About us

We make it our mission to enter into strategic partnerships for the acquisition, development and commercialisation of a robust portfolio of assets that are consistent with the vision of the Company, and to deliver value to our shareholders

Our model: Synergism optimised

The development of novel treatments is urgent for patients who suffer from potentially debilitating conditions and for whom there is no satisfactory standard of care. In order to address this need, our strategy is designed to optimise the time- and resource-efficient development of our pipeline candidates and for process excellence:

SynDermix identifies and acquires the rights to novel and commercially attractive assets from early-stage biopharmaceutical developers, academic research hubs or other companies following the discovery or pre-clinical phases of development

We then devote our resources to the state-of-the-art manufacturing of our pipeline candidates and to the robust demonstration of their innovation and clinical value — a set of activities that we outsource to our specialist partners, benefitting from their know-how and regulatory insights

For our products to reach patients, we out-license or divest the products to our corporate partners with the resources and expertise for commercialisation


We are committed to values that we believe foster and sustain successful teamwork and partnerships, to innovation, and patient centricity:

We value integrity, dedication and fairness; we believe that success is achieved by people with a diverse range of talents and through mutual, synergistic efforts; we are driven by passion and professionalism

We view continued innovation as the answer to unmet and changing healthcare needs, and consider patient convenience as an equally important feature (together with efficacy and safety) in the therapies we select for development and commercialisation

Executive Team

We operate a lean structure, which leverages the complementary expertise of a seasoned executive team, distinguished service providers and key opinion leaders.

Konstantinos Efthymiopoulos, PharmD, PhD, MBA – Chief Executive Officer

Over 30 years’ international experience in big pharma, biotech and VC-backed companies (Farmitalia-Carlo Erba, Glaxo/GlaxoWelcome, Serono, Eurand, Funxional Therapeutics, Index Ventures) at increasingly senior levels that culminated in CSO, CEO and board positions. He is currently the Chairman of the Board of Synaffix BV and Biopôle SA, a Board Director of Metis Precision Medicine and the founder and Managing Director of PLUS Life Sciences Consulting Sàrl.

Jessica Kourniakti, DPhil – Chief Operating Officer

Over 5 years’ experience in independent research and original communications development; past roles include: Teaching Fellow at the University of Oxford (2016–17), conference leadership and executive roles in academic societies (2015–17) and Marketing Manager at MastihaWorld Ltd. (2014­–15); obtained a BA from the University of Bristol (2010), MA from University College London (2011) and DPhil from the University of Oxford (2018), and has published original research in peer-reviewed journals and collective volumes.

Carlos Camozzi, MD, PhD, MBA – Clinical & Regulatory Development

Over 25 years’ international senior management experience in the biopharmaceutical industry (Roche, American Cyanamid, Mepha AG, Orphan Europe, UniQure, Orphazyme). Successfully led several regulatory achievements with both the EMA and the FDA. He is a permanent expert in the European Commission for Eureka and H2020 grant frames, and an expert in rare diseases and orphan drugs.

Rolf Küng, MBA – Finance & Controlling

A Swiss Certified Accountant and co-founder of the Institute For Innovative Trading (IFIT) in 1998. 17 years’ experience in auditing (Touche Ross, Deloitte Haskins & Sells, Grant Thornton and others). Has been a director and CEO of several companies within the IFIT Group with a focus on business projects in Europe and overseas, and is currently a consultant to ARIA Capital Management with offices in the UK, UAE, Greece and Switzerland.

Anastasia Mantalidi, PhD — Manufacturing, IP & QM

Over 4 years’ experience in industrially funded proprietary research in nanotechnology, and methods’ development optimised for in-situ synchrotron radiation-based techniques. Over 2 years’ experience in quality assurance in the pharma industry. Past positions include: Quality Assurance Specialist at DEMO S.A. Pharmaceuticals (2016–18), X-Ray Absorption Spectroscopy Consultant at Johnson Matthey (2016); science projects’ management and guidance for beamtime experiments (2012–15). Obtained a PhD (2016) and an MSc in Chemical Research (2012) from University College London.


Julian Heinrich, BSc — Administration & Data Management

Over 11 years’ experience in marketing and sales and information technology in the health insurance and finance industries (Munich RE and ERGO Insurance Group); holds a BSc degree in Media Information-Technology from the Hochschule der Medien, Stuttgart and is a qualified management assistant for marketing communications.

Board of Directors

Thomas Mehrling, MD, PhD – Chairman of the Board

Founder and Chairman of TNT Medical Corporation, Zurich, with more than 18 years’ experience in the pharmaceutical industry. Senior positions in different companies and across almost all functions in drug development and commercialisation, including: CEO of EDO GmbH, Basel; Medical Leader at Takeda European R&D Centre; Senior Vice President of Medical Affairs at Staticon International; and Head of Business Development (2000-4), European Director of Oncology (2004-11), and International Director of Oncology Strategy (2011-13) at Mundipharma International Ltd. During his tenure as Director of Oncology with Mundipharma, two major products were successfully launched in Europe: DepoCyte® and Levact® (Ribomustin®, Treanda®). A certified Pharmacist with a Ph.D. in pharmacology and a certified physician with an M.D. in haemato-oncology (both from Frankfurt University).

Konstantinos Efthymiopoulos, PharmD, PhD, MBA – Delegate of the Board

See Executive Team above.

Dieter Hemmer – Member of the Board

15 years’ senior executive experience at Nestlé as Head of the Strategic Business Unit (Nestlé Professional Food Services) and Chairman of the Pro Gastronomia Nestlé Foundation. Prior to Nestlé, he spent 22 years in a number of senior executive positions with Lufthansa, including Head of Global Inflight Service and Managing Director for Lufthansa Service (LSG) Asia. BSc in Economics from FHS Heidelberg and management education at INSEAD, London Business School and IMD.


IP, regulatory & corporate


Intellectual property company, London


Patent and law office, Budapest


Regulatory consulting and services, Munich

ARIA Services

Financial and administrative services, Zurich


Attorneys at law, Zurich


Tax consulting and audit services, Zurich

Bioscience Valuation

Biotechnology and pharmaceutical company economic, R&D and value assessors and consultants, Garmins

Manufacturing, Clinical & Non-Clinical

Fujifilm Diosynth

Biotechnologies manufacturer, Billingham


Professional inventors, Biel 


Clinical research organisation, Biel 

IQVIA Solutions

Multinational contract research organisation, Durham, NC

King’s College London

Institute of Pharmaceutical Science KCL, University of London